Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec 25;64(4):332-334.
doi: 10.3960/jslrt.24054. Epub 2024 Nov 28.

Treatment with epcoritamab in 10 patients in real-world clinical practice

Yasunobu Sekiguchi  1 , Hiroki Tsutsumi  1 , Masahisa Kudo  1 , Nobuo Maseki  1 , Yoshie Iizaki  1 , Machiko Kawamura  1   2 , Kazuhiko Kobayashi  3 , Yu Nishimura  4 , Hiroaki Kanda  4 , Daisuke Takei  5 , Tomoya Abe  5 , Makoto Hanai  5 , Toshiaki Nakayama  5 , Yasumasa Shimano  6 , Hirofumi Kobayashi  1
Affiliations

Treatment with epcoritamab in 10 patients in real-world clinical practice

Yasunobu Sekiguchi et al. J Clin Exp Hematop. .
No abstract available

Keywords: 3rd line; BsAb; epcoritamab; real world; relapsed/refractory diffuse large B-cell lymphoma.

PubMed Disclaimer

Conflict of interest statement

CONFLICT OF INTEREST

YS: Lecture fees from Chugai Pharmaceutical Co., Ltd.

Figures

Fig. 1
Fig. 1
Swimmer plot Abbreviations: CR, complete remission; PD, progressive disease; PR, partial remission; SD, stable disease; C, cycle; LSC, late segmental collapse
See this image and copyright information in PMC

References

    1. Thieblemont C, Phillips T, Ghesquieres H, et al. Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial. J Clin Oncol. 2023; 41: 2238-2247. - PMC - PubMed
    1. Izutsu K, Kumode T, Yuda J, et al. Subcutaneous epcoritamab monotherapy in Japanese adults with relapsed/refractory diffuse large B-cell lymphoma. Cancer Sci. 2023; 114: 4643-4653. - PMC - PubMed
    1. Iacoboni G, Serna A, Garces VN, et al. Impact of Prior Bendamustine Exposure on Bispecific Antibody Treatment Outcomes for Patients with B-Cell Lymphoma. Blood. 2023; 142: 310.
    1. van der Horst HJ, de Jonge AV, Hiemstra IH, et al. Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment. Blood Cancer J. 2021; 11: 38. - PMC - PubMed
    1. Lee DW, Santomasso BD, Locke FL, et al. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. Biol Blood Marrow Transplant. 2019; 25: 625-638. - PubMed